治疗耐药性胆固醇化症的阿达利穆马布治疗方法
1Ege University Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey.
Reumatologia clinica
|October 13, 2024
概括
耐药性胆固醇 (也称为酸沉积疾病或CPPD) 显示在皮下治疗阿达利姆巴治疗后显著改善. 这项研究强调了抗瘤坏死因子治疗作为严重的CPPD病例的可行的二线选择.
科学领域:
- 类风湿病学 类风湿病学
- 免疫学 免疫学 免疫学
- 结晶诱导的关节炎
背景情况:
- 胆固醇或酸盐沉积疾病 (CPPD) 是一种结晶诱导的关节病,其特点是酸盐二 (CPPD) 晶体沉积在软骨和其他组织中.
- 耐药性CPPD病例往往带来重大管理挑战,需要探索替代治疗策略.
- 瘤亡因子 (TNF) 在与各种晶体诱导关节病相关的炎症过程中发挥作用.
研究的目的:
- 报告阿达利穆马布在患有重症,耐治疗性胆固醇症的患者的成功使用情况.
- 评估抗瘤亡因子 (TNF) 治疗作为中风性肺炎第二线治疗的疗效.
主要方法:
- 一个病例研究,一个患有严重冠状腺结症的病人,常规疗法失败了.
- 40毫克的皮下注射阿达利穆马布的管理.
- 监测患者对治疗的反应.
主要成果:
- 该患者对皮下阿达利穆马布治疗表现出良好的临床反应.
- 这代表了第一个报告的阿达利穆马布在严重的CPPD中成功使用的情况.
结论:
- 对于患有重症,耐药性胆固醇症的患者来说,阿达利穆马布可以是一个有效的治疗选择.
- 抗TNF疗法显示出作为一种有价值的二线治疗酸盐沉积疾病 (CPPD) 的潜力.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
143
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
143
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
117
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
117
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
97
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
97
Alzheimer's Disease: Treatment
166
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
166
Drugs for Treatment of Ulcerative Colitis in IBD
126
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
126
Myasthenia Gravis: Overview and Treatment
1.2K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.2K


